Journey Medical (NASDAQ:DERM) Trading Up 3.2%

Journey Medical Co. (NASDAQ:DERM) rose 3.2% during trading on Wednesday . The company traded as high as $5.17 and last traded at $5.14. Approximately 56,930 shares changed hands during trading, a decline of 63% from the average daily volume of 155,540 shares. The stock had previously closed at $4.98.

Journey Medical Trading Up 3.2 %

The company has a current ratio of 1.21, a quick ratio of 0.94 and a debt-to-equity ratio of 1.13. The firm has a market capitalization of $102.87 million, a price-to-earnings ratio of -16.58 and a beta of 0.79. The business’s 50-day moving average price is $4.13.

Journey Medical (NASDAQ:DERM) last released its earnings results on Monday, May 13th. The company reported ($0.53) EPS for the quarter, missing analysts’ consensus estimates of ($0.26) by ($0.27). Journey Medical had a negative return on equity of 32.83% and a negative net margin of 5.20%. The company had revenue of $13.03 million during the quarter, compared to analyst estimates of $14.91 million. Analysts expect that Journey Medical Co. will post -1.02 earnings per share for the current year.

Institutional Investors Weigh In On Journey Medical

A number of large investors have recently modified their holdings of the business. Heron Bay Capital Management purchased a new stake in shares of Journey Medical in the first quarter valued at about $124,000. Acadian Asset Management LLC lifted its position in shares of Journey Medical by 687.5% during the first quarter. Acadian Asset Management LLC now owns 222,663 shares of the company’s stock worth $817,000 after purchasing an additional 194,389 shares in the last quarter. Finally, Nwam LLC acquired a new stake in shares of Journey Medical during the first quarter worth about $41,000. Hedge funds and other institutional investors own 7.25% of the company’s stock.

About Journey Medical

Journey Medical Corporation focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant nodular acne; and Amzeeq, a topical formulation of minocycline for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris.